InterMed Discovery Announces Collaboration Agreement with the Lead Discovery Center
News Apr 03, 2009
InterMed Discovery (IMD) has announced the start of a screening project for the Lead Discovery Center GmbH (LDC), a Max-Planck-Innovation company.
The LDC was founded in 2008 in close proximity to IMD at the University Campus at Dortmund and forms an essential part of Max-Planck-Innovation's Drug Discovery & Development Center (DDC).
The objective of this collaboration project between IMD and the LDC is to identify naturally derived modulators by screening IMD’s natural product libraries against targets provided by LDC and based on intellectual property previously generated by MPG and the LDC.
IMD will undertake assay establishment, screening, hit identification and hit validation for LDC using its expertise and technology platform with the largest collection of pure natural products (NAT-PURER®) and fractionated extracts (PRE-FRACR®).
“We intend this to be the beginning of a long term relationship with more projects coming in the very near future,” said Bernard Becker, Managing Director of InterMed Discovery. “This is a step forward in our sustainable business growth through integrated research-based value generation validating our strong research capabilities.”
Dr Bert Klebl, Managing Director & CSO added: “The LDC aims to achieve the very highest levels of quality in early drug discovery and this objective is greatly enhanced by the collaboration with InterMed Discovery.”
In a new study in cells, University of Illinois researchers have adapted CRISPR gene-editing technology to cause the cell’s internal machinery to skip over a small portion of a gene when transcribing it into a template for protein building. This gives researchers a way not only to eliminate a mutated gene sequence, but to influence how the gene is expressed and regulated.